M2 cells develop defective NF-κB activation during tumor progression by constitutive formation of p50 homodimers, leading to a reduced expression of iNOS accompanied by an impaired ability to produce NO and a reduced TNF-α secretion [58]. The gene discussed is NFKB1; the disease is neoplasm.